President of pioneering hydrocarbon biofuels company to accept honor in Davos, Switzerland

Agreement Highlights Growing Interest in Novel Biology Platform that Identifies Clinical Response of Cancer Drugs

LEXINGTON, Mass., December 18, 2007 – CoNCERT Pharmaceuticals Inc., the first company dedicated to creating new medicines using precision modification chemistry with the naturally-occurring element deuterium, announced today the appointment of Ronald W. Barrett, Ph.D. to its Board of Directors. Dr. Barrett is chief executive officer, co-founder and director of XenoPort, Inc. (NASDAQ: XNPT), a biopharmaceutical company focused on developing a portfolio of internally discovered products candidates for the potential treatment of central nervous system disorders.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing “smart” therapeutic targeted nanoparticles capable of controlled drug delivery to diseased tissue, announced today the appointment of Jim Wright, Ph.D., as Chief Scientific Officer.

Next phase of the High-Risk Plaque Initiative will leverage advances in diagnostic imaging and blood biomarker science to reduce morbidity, mortality and cost associated with cardiovascular disease

Quanterix Technology Shown To Be More Than 1,000 Times More Sensitive Than Standard Methods With Potential For Broad Application To Measure Biomarkers In Cancer, Autoimmune, and Neurological Diseases

Physic Ventures Leads Financing in Novel Technology to Enable Decentralized Diagnostics

CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M. Bate, president and chief executive officer of NitroMed, Inc., to its Board of Directors.

Cambridge, MA -- January 3, 2008 – T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance imaging (MRI) technology, today announced the appointment of John McDonough as Chief Executive Officer. McDonough will also serve as a member of the Company’s board of directors.

CAMBRIDGE, Mass., Jan 04, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation announced today that it has closed a $20 million senior secured credit facility with GE Healthcare Financial Services. The Company will use the credit facility to support working capital and commercialization efforts.